Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes

Fernando Álvarez-Guisasola; Domingo Orozco-Beltrán; Ana M. Cebrián-Cuenca; Manuel Antonio Ruiz Quintero; Escarlata Angullo Martínez; Luis Ávila Lachica; Carlos Ortega Millán; Elena Caride Miana; Jorge Navarro-Pérez; Julio Sagredo Perez; Joan Barrot de la Puente; Francesc Xavier Cos Claramunt

doi:10.1016/j.aprim.2019.05.014

Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes

Fernando Álvarez-Guisasola, Domingo Orozco-Beltrán, Ana M. Cebrián-Cuenca, Manuel Antonio Ruiz Quintero, Escarlata Angullo Martínez, Luis Ávila Lachica, Carlos Ortega Millán, Elena Caride Miana, Jorge Navarro-Pérez, Julio Sagredo Perez, Joan Barrot de la Puente, Francesc Xavier Cos Claramunt

Department of Medicine

Research output: Contribution to journal › Article › Research

2 Citations (Scopus)

Abstract

© 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.

Original language	English
Pages (from-to)	442-451
Journal	Atencion Primaria
Volume	51
DOIs	https://doi.org/10.1016/j.aprim.2019.05.014
Publication status	Published - 1 Aug 2019

Keywords

Antidiabetic drugs
Hyperglycemia
Type 2 diabetes

Access to Document

10.1016/j.aprim.2019.05.014

Fingerprint Dive into the research topics of 'Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes'. Together they form a unique fingerprint.

Cite this

Álvarez-Guisasola, F., Orozco-Beltrán, D., Cebrián-Cuenca, A. M., Ruiz Quintero, M. A., Angullo Martínez, E., Ávila Lachica, L., Ortega Millán, C., Caride Miana, E., Navarro-Pérez, J., Sagredo Perez, J., Barrot de la Puente, J., & Cos Claramunt, F. X. (2019). Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes. Atencion Primaria, 51, 442-451. https://doi.org/10.1016/j.aprim.2019.05.014

Álvarez-Guisasola, Fernando ; Orozco-Beltrán, Domingo ; Cebrián-Cuenca, Ana M. ; Ruiz Quintero, Manuel Antonio ; Angullo Martínez, Escarlata ; Ávila Lachica, Luis ; Ortega Millán, Carlos ; Caride Miana, Elena ; Navarro-Pérez, Jorge ; Sagredo Perez, Julio ; Barrot de la Puente, Joan ; Cos Claramunt, Francesc Xavier. / Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes. In: Atencion Primaria. 2019 ; Vol. 51. pp. 442-451.

@article{5b91a274e3254745b2e4a0e19e1d6cf9,

title = "Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes",

abstract = "{\textcopyright} 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.",

keywords = "Antidiabetic drugs, Hyperglycemia, Type 2 diabetes",

author = "Fernando {\'A}lvarez-Guisasola and Domingo Orozco-Beltr{\'a}n and Cebri{\'a}n-Cuenca, {Ana M.} and {Ruiz Quintero}, {Manuel Antonio} and {Angullo Mart{\'i}nez}, Escarlata and {{\'A}vila Lachica}, Luis and {Ortega Mill{\'a}n}, Carlos and {Caride Miana}, Elena and Jorge Navarro-P{\'e}rez and {Sagredo Perez}, Julio and {Barrot de la Puente}, Joan and {Cos Claramunt}, {Francesc Xavier}",

year = "2019",

month = aug,

day = "1",

doi = "10.1016/j.aprim.2019.05.014",

language = "English",

volume = "51",

pages = "442--451",

journal = "Atencion Primaria",

issn = "0212-6567",

publisher = "Ediciones Doyma, S.L.",

}

Álvarez-Guisasola, F, Orozco-Beltrán, D, Cebrián-Cuenca, AM, Ruiz Quintero, MA, Angullo Martínez, E, Ávila Lachica, L, Ortega Millán, C, Caride Miana, E, Navarro-Pérez, J, Sagredo Perez, J, Barrot de la Puente, J & Cos Claramunt, FX 2019, 'Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes', Atencion Primaria, vol. 51, pp. 442-451. https://doi.org/10.1016/j.aprim.2019.05.014

Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes. / Álvarez-Guisasola, Fernando; Orozco-Beltrán, Domingo; Cebrián-Cuenca, Ana M.; Ruiz Quintero, Manuel Antonio; Angullo Martínez, Escarlata; Ávila Lachica, Luis; Ortega Millán, Carlos; Caride Miana, Elena; Navarro-Pérez, Jorge; Sagredo Perez, Julio; Barrot de la Puente, Joan; Cos Claramunt, Francesc Xavier.

In: Atencion Primaria, Vol. 51, 01.08.2019, p. 442-451.

Research output: Contribution to journal › Article › Research

TY - JOUR

T1 - Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes

AU - Álvarez-Guisasola, Fernando

AU - Orozco-Beltrán, Domingo

AU - Cebrián-Cuenca, Ana M.

AU - Ruiz Quintero, Manuel Antonio

AU - Angullo Martínez, Escarlata

AU - Ávila Lachica, Luis

AU - Ortega Millán, Carlos

AU - Caride Miana, Elena

AU - Navarro-Pérez, Jorge

AU - Sagredo Perez, Julio

AU - Barrot de la Puente, Joan

AU - Cos Claramunt, Francesc Xavier

PY - 2019/8/1

Y1 - 2019/8/1

N2 - © 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.

AB - © 2019 Treatment of diabetes mellitus type 2 (DM2) includes healthy eating and exercise (150 minutes/week) as basic pillars. For pharmacological treatment, metformin is the initial drug except contraindication or intolerance; in case of poor control, 8 therapeutic families are available (6 oral and 2 injectable) as possible combinations. An algorithm and some recommendations for the treatment of DM2 are presented. In secondary cardiovascular prevention, it is recommended to associate an inhibitor of the sodium-glucose cotransporter type 2 (iSGLT2) or a glucagon-like peptide-1 receptor agonist (arGLP1) in patients with obesity. In primary prevention if the patient is obese or overweight metformin should be combined with iSGLT2, arGLP1, or inhibitors of type 4 dipeptidylpeptidase (iDPP4). If the patient does not present obesity, iDPP4, iSGLT2 or gliclazide, sulfonylurea, recommended due to its lower tendency to hypoglycaemia, may be used.

KW - Antidiabetic drugs

KW - Hyperglycemia

KW - Type 2 diabetes

U2 - 10.1016/j.aprim.2019.05.014

DO - 10.1016/j.aprim.2019.05.014

M3 - Article

C2 - 31320123

VL - 51

SP - 442

EP - 451

JO - Atencion Primaria

JF - Atencion Primaria

SN - 0212-6567

ER -